In this article, we will take a look at the 5 Cash-Rich Dividend Stocks to Invest In Right Now. For a deeper discussion and analysis, have a look at the 15 Cash-Rich Dividend Stocks to Invest In Right Now. 

5. Cardinal Health, Inc. (NYSE:CAH)

Operating Cash Flow (TTM): $6.1 Billion

On April 8, Evercore ISI analyst Elizabeth Anderson lowered the price recommendation on Cardinal Health, Inc. (NYSE:CAH) to $240 from $260. It reiterated an Outperform rating on the shares. The firm made several adjustments as part of its Q1 preview for healthcare technology and distribution, including updates to its Tactical call lists.

Earlier, on April 1, Cardinal Health said it is expanding production of Actinium-225 (Ac-225) at its theranostics center in Indianapolis. The company is adding a high-capacity production line, which it expects will meaningfully increase the supply of cGMP-compliant Ac-225 for clinical research and future commercial use.

The company explained that Ac-225 is a radioactive isotope used in targeted cancer treatments. It is attached to molecules that locate and destroy cancer cells. Interest in these therapies continues to grow across different cancer types, though limited global supply has slowed progress. Since ramping up production in late 2024, Cardinal Health said it has already increased its weekly output fourfold. It expects to expand capacity further in 2026 as demand continues to build.

The company also said the expanded production is improving access for both research and clinical use. Its Ac-225 has been used in more than 15 clinical trials worldwide and has supported regulatory filings for customers in several regions.

Cardinal Health, Inc. (NYSE:CAH) operates as a distributor of pharmaceuticals and specialty products. It also manufactures and distributes medical and laboratory products, provides home-health and direct-to-patient services, runs nuclear pharmacies and manufacturing facilities, and offers performance and data solutions.

4. Altria Group, Inc. (NYSE:MO)

Operating Cash Flow (TTM): $9.29 Billion

On April 10, BofA analyst Lisa Lewandowski raised the price recommendation on Altria Group, Inc. (NYSE:MO) to $73 from $72. It reiterated a Buy rating on the shares. The firm also increased its EPS estimates for 2026 and 2027 to $5.60 and $5.84.The updated outlook reflects expectations for a more moderate decline in cigarette volumes, helped by improved enforcement against illicit trade. At the same time, the firm still sees ongoing consumer pressure weighing on volumes.

Earlier, on March 23, the company announced a national retail expansion of on! PLUS nicotine pouches. The product is made by Helix Innovations LLC, an Altria operating company. on! PLUS is the first product authorized under the U.S. Food and Drug Administration’s pilot program aimed at speeding up the review of nicotine pouch applications. The product comes in three flavors and two nicotine strengths. It also includes proprietary NICOSILK technology and a built-in compartment for responsible disposal.

The company had already been offering the product through e-commerce and select retailers in North Carolina, Florida, and Texas. Wholesale deliveries for the broader rollout began on March 16, 2026.

Altria Group, Inc. (NYSE:MO) sells tobacco products in the United States for consumers aged 21 and older. Its business is split between smokeable products and oral tobacco products. The smokeable segment includes cigarettes and machine-made large cigars.

3. McKesson Corporation (NYSE:MCK)

Operating Cash Flow (TTM): $10.48 Billion

On April 8, Evercore ISI lowered its price recommendation on McKesson Corporation (NYSE:MCK) to $950 from $1,000. It reiterated an Outperform rating on the shares. The changes came as part of its Q1 preview for healthcare technology and distribution, along with updates to its Tactical call lists. As part of those moves, the firm also added McKesson to its “Tactical Underperform” list.

A couple of days earlier, on April 6, BofA analyst Allen Lutz reduced his price target to $1,000 from $1,040 while maintaining a Buy rating. He pointed to the rapid decline in cash-pay GLP-1 prices as a key factor. He said the shift toward cash-pay prescriptions for Wegovy and Zepbound could weigh on McKesson’s FY27 EBIT outlook in its Prescription Technology Solutions segment. In his view, this trend may cause results to come in below Street expectations.

McKesson Corporation (NYSE:MCK) operates as a diversified healthcare services company focused on improving patient outcomes. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter drugs, along with other healthcare-related products across the United States.

2. Bristol-Myers Squibb Company (NYSE:BMY)

Operating Cash Flow (TTM): $14.16 Billion

On April 9, BofA analyst Jason Gerberry lowered the price recommendation on Bristol-Myers Squibb Company (NYSE:BMY) to $67 from $68. It reiterated a Buy rating on the shares. The firm made several adjustments alongside its Q1 preview for large-cap pharma and small- to mid-cap biopharma coverage.

During the Q4 2025 earnings call, management said it expects 2026 revenue to come in between $46 billion and $47.5 billion. The company pointed to steady performance in its growth portfolio, while also noting that a 12% to 16% decline in the legacy portfolio is likely as exclusivity losses continue to weigh on results. The company also expects Eliquis to grow by 10% to 15% in 2026. Adjusted diluted EPS is projected in the range of $6.05 to $6.35.

CFO David Elkins said gross margins are expected to be between 69% and 70%. He also noted that total operating expenses should decline from 2025 levels to around $16.3 billion. Looking ahead, management indicated that Eliquis sales could fall by $1.5 billion to $2 billion in 2027 compared to 2026, mainly due to patent expirations in Europe.

Bristol-Myers Squibb Company (NYSE:BMY) operates as a global biopharmaceutical company focused on developing and delivering medicines for serious diseases. Its work spans oncology, hematology, immunology, cardiovascular, neuroscience, and other areas.

1. American Express Company (NYSE:AXP)

Operating Cash Flow (TTM): $18.43 Billion

On April 10, RBC Capital lowered its price recommendation on American Express Company (NYSE:AXP) to $415 from $425. It reiterated an Outperform rating on the shares. The update came as part of its Q1 preview for consumer finance names. The firm expects seasonal trends to lead to lower loan balances, while credit metrics remain stable or improve year over year. It also said upcoming conference calls will likely focus on consumer sentiment and overall financial health, especially with recent macro volatility. Even so, RBC believes that “fundamentals remain healthy”.

A day earlier, on April 9, Wells Fargo also reduced its price objective on American Express to $415 from $425. It maintained an Overweight rating on the shares. The firm said that as war-related risks ease, attention is shifting toward concerns around AI and job security, where investor sentiment appears cautious. Wells noted that credit trends and card spending are holding up well, and said stimulus effects are expected to outweigh pressure from gas prices. The firm also expects banks to maintain a constructive tone toward the consumer in the coming week.

American Express Company (NYSE:AXP) operates as a global payments and premium lifestyle brand supported by technology. Its card-issuing, merchant-acquiring, and network businesses serve a wide range of customers, including individuals, small businesses, mid-sized firms, and large corporations worldwide.

READ NEXT: 13 NASDAQ Stocks with Highest Dividends and 15 Best Cheap Dividend Stocks to Buy

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.